RFA-CA-21-025: Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $750,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 4 awards worth $4.6 million in total. Applications closed on July 30, 2021.
From the official notice on Grants.gov, last changed April 5, 2021. Checked November 7, 2026.
- Award ceiling$750,000
- Total funding$4.6 million
- Expected awards4
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$1.1 million
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-21-025 were run by National Cancer Institute (NCI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-21-025 in the NIH Guide.
Key dates
| Posted | April 5, 2021 |
|---|---|
| Deadline | July 30, 2021 |
| Archived by Grants.gov | September 4, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.1 million; it allows up to $750,000 per award.
- Most of the money in the 2 programs behind this notice (58% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) is a part of the NCI, Division of Cancer Treatment and Diagnosis (DCTD), Office of Cancer Clinical Proteomics Research (OCCPR), Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating research resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.
Funded under RFA-CA-21-025 so far
NIH funded 4 projects under RFA-CA-21-025 in fiscal 2022 to 2026, at 4 institutions. The median yearly award was $1.1 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia | Oregon Health & Science University | 2026 | $1.2 million |
| Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies | Fred Hutchinson Cancer Center | 2026 | $829,054 |
| Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer | Washington University | 2026 | $1.0 million |
| Mayo Clinic Center for Clinical Proteomics | Mayo Clinic Rochester | 2026 | $1.1 million |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-21-025 still open?
No. It closed on July 30, 2021.
Who can apply for Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)?
Closed July 30, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each. About $4.6 million in total across about 4 awards.
Who has been funded under RFA-CA-21-025?
NIH RePORTER lists 4 projects funded under RFA-CA-21-025 in fiscal 2022 to 2026, at 4 institutions. The most were at Oregon Health & Science University, Fred Hutchinson Cancer Center, Washington University.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)